Clinical trials
for patients
Learn about available clinical trials



-
July 3, 2025Pamplona/MadridIn recruitment
ART0380C001 Trial of ART0380 as oral and gemcitabine treatment in patients with advanced or metastatic solid tumor
The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th... -
July 3, 2025MadridIn recruitmentEarly phase
BAY 2927088 / 22752 Clinical trial with BAY 2927088 tablets for in patients who have a solid tumor with human epidermal growth factor receptor 2 mutations
The main objective is to evaluate the efficacy of BAY 2927088 in objective response rate (ORR) assessed by blinded independent centralized review (BICR). -
July 3, 2025MadridIn recruitmentEarly phase
DS6000-126 Phase II clinical trial to evaluate the efficacy and safety of Raludotatug Deruxtecan (R-DXd) in advanced or metastatic solid tumors
The main objective is to evaluate the efficacy of R-DXd treatment as measured by ORR as assessed by the investigator. -
June 30, 2025Pamplona/MadridIn recruitmentEarly phase
D967VC00001 Trastuzumab Deruxtecan trial for the treatment of selected HER2-expressing tumors.
We are conducting this trial to learn more about how trastuzumab deruxtecan could provide benefits to cancer patients. The purpose of this trial is to determine the efficacy and safety of the trial drug for the treatment of a type of locally advanced solid cancer based on the level of HER2 protein expression and, in addition, to learn more about the disease being studied and the associated health problems. -
June 30, 2025PamplonaIn recruitmentEarly phase
1438-0001 Clinical trial to evaluate different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3
The objective of this study is to determine the most appropriate dose of BI 764532 to be received in the future by patients with a cancer like yours who progressed after treatment with available standard treatments, including platinum therapy, or who are ineligible for available standard treatments. Only patients confirmed positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study. -
June 30, 2025Pamplona/MadridIn recruitment
-
June 23, 2025Pamplona/MadridIn recruitment
MCLA-129-CL01 Clinical trial of MCLA-129 in patients with advanced NSCLC and other solid tumors
The aim of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug. -
June 23, 2025Pamplona/MadridIn recruitmentEarly phase
RAY902CT Unmasked assay of RAY21 to inhibit the classical complement pathway in immunological diseases
The main objective is to evaluate the safety and tolerability of multiple s.c. administrations of RAY121 in patients with complement immunodeficiencies -
June 17, 2025Pamplona/MadridIn recruitment
20210181 Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and tolerability of maridebart cafraglutide in adult participants without type 2 diabetes mellitus who are obese or overweight.
This study is being conducted to test whether maridebart cafraglutide [MariTide (formerly AMG 133)] is a safe drug, can reduce body weight, and can improve weight-related conditions in people like you who are living with obesity or being overweight, but do not have type 2 diabetes (T2DM, a disease that occurs when blood sugar levels are too high). -
June 16, 2025PamplonaIn recruitmentEarly phase
MPSA-153-002 EC in combination of NMS-01940153E and atezolizumab with or without prior low-dose decitabine for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors.
The aim of this study is to learn about the safety, tolerability and antitumor properties of NMS-01940153E administered with atezolizumab and with or without decitabine for the treatment of hepatocellular carcinoma (HCC).